Dermapharm Holding SE
Research Dermapharm Holding SE (DMP) on Bullrun: valuation model: 31.5% undervalued, market cap EUR 2.33B, P/E 17.5, dividend yield 1.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDMP
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Valuation signal31.5% undervalued
- Market capEUR 2.33B
- P/E17.5
- Dividend yield1.9%
- Financial periodQ3 2025
- RevenueEUR 294.90M
- Net incomeEUR 41.23M
- Free cash flowEUR 54.94M
- Gross margin66.4%
Valuation Snapshot
Bullrun's latest valuation model marks Dermapharm Holding SE as 31.5% undervalued; latest market cap is EUR 2.33B; P/E is 17.5; dividend yield is 1.9%.
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business.
Frequently asked questions
Is Dermapharm Holding SE overvalued or undervalued?
Bullrun's valuation model currently marks Dermapharm Holding SE as 31.5% undervalued.
What is Dermapharm Holding SE's market cap?
Dermapharm Holding SE's market capitalization is EUR 2.33B.
What is Dermapharm Holding SE's P/E ratio?
Dermapharm Holding SE's price-to-earnings (P/E) ratio is 17.5.
Does Dermapharm Holding SE pay a dividend?
Dermapharm Holding SE has a dividend yield of 1.9%.
What does Dermapharm Holding SE do?
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China.